+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Acinetobacter Infections - Pipeline Review, H2 2019

  • ID: 4901294
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 181 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • ABAC Therapeutics SA
  • Antabio SAS
  • ContraFect Corp
  • F. Hoffmann-La Roche Ltd
  • Meiji Seika Pharma Co Ltd
  • Oxford Drug Design Ltd
  • MORE
Acinetobacter Infections - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Acinetobacter Infections - Pipeline Review, H2 2019, provides an overview of the Acinetobacter Infections (Infectious Disease) pipeline landscape.

Acinetobacter is a gram-negative coccobacillus. Acinetobacter infections are uncommon but, when they occur, usually involve organ systems that have a high fluid content (respiratory tract, CSF, peritoneal fluid, urinary tract). Symptoms include fever (high body temperature), red, swollen, warm or painful skin areas or wounds. Predisposing factors include weak immune system, poor hygiene and recent surgery or procedure.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Acinetobacter Infections - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Acinetobacter Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acinetobacter Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Acinetobacter Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 5, 1, 37 and 17 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 7 molecules, respectively.

Acinetobacter Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acinetobacter Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Acinetobacter Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acinetobacter Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acinetobacter Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acinetobacter Infections (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acinetobacter Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acinetobacter Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • ABAC Therapeutics SA
  • Antabio SAS
  • ContraFect Corp
  • F. Hoffmann-La Roche Ltd
  • Meiji Seika Pharma Co Ltd
  • Oxford Drug Design Ltd
  • MORE
Introduction
Report Coverage
Acinetobacter Infections - Overview
Acinetobacter Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Acinetobacter Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Acinetobacter Infections - Companies Involved in Therapeutics Development
ABAC Therapeutics SA
Abgentis Ltd
Acies Bio doo
AGILeBiotics BV
AiCuris GmbH & Co KG
Antabio SAS
Appili Therapeutics Inc
Aridis Pharmaceuticals Inc
Armata Pharmaceuticals Inc
AstraZeneca Plc
Atterx Biotherapeutics Inc
Aurora Oncology Inc
Bioharmony Therapeutics Inc
Biomendics LLC
Bugworks Research India Pvt Ltd
ContraFect Corp
Destiny Pharma Plc
Eligochem Ltd
EnBiotix Inc
Entasis Therapeutics Inc
F. Hoffmann-La Roche Ltd
Fedora Pharmaceuticals Inc
Hsiri Therapeutics LLC
Inhibrx Inc
KBP BioSciences Co Ltd
Linnaeus Bioscience Inc
Meiji Seika Pharma Co Ltd
Melinta Therapeutics Inc
Neoculi Pty Ltd
Novabiotics Ltd
Octagon Therapeutics Inc
Oxford Drug Design Ltd
Peptilogics Inc
Pylum Biosciences Inc
Qpex Biopharma Inc
Redx Pharma Plc
RMH Sciences LLC
Sealife PHARMA GMBH
Shanghai Space Peptides Pharmaceutical Co Ltd
Shionogi & Co Ltd
Spero Therapeutics Inc
Summit Therapeutics Plc
Tetraphase Pharmaceuticals Inc
VenatoRx Pharmaceuticals Inc
Venus Medicine Research Center
Vitas Pharma Research Pvt Ltd
Xellia Pharmaceuticals ApS
Acinetobacter Infections - Drug Profiles
Acinetobacter Infections - Dormant Projects
Acinetobacter Infections - Discontinued Products
Acinetobacter Infections - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Acinetobacter Infections, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Acinetobacter Infections - Pipeline by ABAC Therapeutics SA, H2 2019
Acinetobacter Infections - Pipeline by Abgentis Ltd, H2 2019
Acinetobacter Infections - Pipeline by Acies Bio doo, H2 2019
Acinetobacter Infections - Pipeline by AGILeBiotics BV, H2 2019
Acinetobacter Infections - Pipeline by AiCuris GmbH & Co KG, H2 2019
Acinetobacter Infections - Pipeline by Antabio SAS, H2 2019
Acinetobacter Infections - Pipeline by Appili Therapeutics Inc, H2 2019
Acinetobacter Infections - Pipeline by Aridis Pharmaceuticals Inc, H2 2019
Acinetobacter Infections - Pipeline by Armata Pharmaceuticals Inc, H2 2019
Acinetobacter Infections - Pipeline by AstraZeneca Plc, H2 2019
Acinetobacter Infections - Pipeline by Atterx Biotherapeutics Inc, H2 2019
Acinetobacter Infections - Pipeline by Aurora Oncology Inc, H2 2019
Acinetobacter Infections - Pipeline by Bioharmony Therapeutics Inc, H2 2019
Acinetobacter Infections - Pipeline by Biomendics LLC, H2 2019
Acinetobacter Infections - Pipeline by Bugworks Research India Pvt Ltd, H2 2019
Acinetobacter Infections - Pipeline by ContraFect Corp, H2 2019
Acinetobacter Infections - Pipeline by Destiny Pharma Plc, H2 2019
Acinetobacter Infections - Pipeline by Eligochem Ltd, H2 2019
Acinetobacter Infections - Pipeline by EnBiotix Inc, H2 2019
Acinetobacter Infections - Pipeline by Entasis Therapeutics Inc, H2 2019
Acinetobacter Infections - Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Acinetobacter Infections - Pipeline by Fedora Pharmaceuticals Inc, H2 2019
Acinetobacter Infections - Pipeline by Hsiri Therapeutics LLC, H2 2019
Acinetobacter Infections - Pipeline by Inhibrx Inc, H2 2019
Acinetobacter Infections - Pipeline by KBP BioSciences Co Ltd, H2 2019
Acinetobacter Infections - Pipeline by Linnaeus Bioscience Inc, H2 2019
Acinetobacter Infections - Pipeline by Meiji Seika Pharma Co Ltd, H2 2019
Acinetobacter Infections - Pipeline by Melinta Therapeutics Inc, H2 2019
Acinetobacter Infections - Pipeline by Neoculi Pty Ltd, H2 2019
Acinetobacter Infections - Pipeline by Novabiotics Ltd, H2 2019
Acinetobacter Infections - Pipeline by Octagon Therapeutics Inc, H2 2019
Acinetobacter Infections - Pipeline by Oxford Drug Design Ltd, H2 2019
Acinetobacter Infections - Pipeline by Peptilogics Inc, H2 2019
Acinetobacter Infections - Pipeline by Pylum Biosciences Inc, H2 2019
Acinetobacter Infections - Pipeline by Qpex Biopharma Inc, H2 2019
Acinetobacter Infections - Pipeline by Redx Pharma Plc, H2 2019
Acinetobacter Infections - Pipeline by RMH Sciences LLC, H2 2019
Acinetobacter Infections - Pipeline by Sealife PHARMA GMBH, H2 2019
Acinetobacter Infections - Pipeline by Shanghai Space Peptides Pharmaceutical Co Ltd, H2 2019
Acinetobacter Infections - Pipeline by Shionogi & Co Ltd, H2 2019
Acinetobacter Infections - Pipeline by Spero Therapeutics Inc, H2 2019
Acinetobacter Infections - Pipeline by Summit Therapeutics Plc, H2 2019
Acinetobacter Infections - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2019
Acinetobacter Infections - Pipeline by VenatoRx Pharmaceuticals Inc, H2 2019
Acinetobacter Infections - Pipeline by Venus Medicine Research Center, H2 2019
Acinetobacter Infections - Pipeline by Vitas Pharma Research Pvt Ltd, H2 2019
Acinetobacter Infections - Pipeline by Xellia Pharmaceuticals ApS, H2 2019
Acinetobacter Infections - Dormant Projects, H2 2019
Acinetobacter Infections - Dormant Projects, H2 2019 (Contd..1), H2 2019
Acinetobacter Infections - Dormant Projects, H2 2019 (Contd..2), H2 2019
Acinetobacter Infections - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Acinetobacter Infections, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • ABAC Therapeutics SA
  • Abgentis Ltd
  • Acies Bio doo
  • AGILeBiotics BV
  • AiCuris GmbH & Co KG
  • Antabio SAS
  • Appili Therapeutics Inc
  • Aridis Pharmaceuticals Inc
  • Armata Pharmaceuticals Inc
  • AstraZeneca Plc
  • Atterx Biotherapeutics Inc
  • Aurora Oncology Inc
  • Bioharmony Therapeutics Inc
  • Biomendics LLC
  • Bugworks Research India Pvt Ltd
  • ContraFect Corp
  • Destiny Pharma Plc
  • Eligochem Ltd
  • EnBiotix Inc
  • Entasis Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Fedora Pharmaceuticals Inc
  • Hsiri Therapeutics LLC
  • Inhibrx Inc
  • KBP BioSciences Co Ltd
  • Linnaeus Bioscience Inc
  • Meiji Seika Pharma Co Ltd
  • Melinta Therapeutics Inc
  • Neoculi Pty Ltd
  • Novabiotics Ltd
  • Octagon Therapeutics Inc
  • Oxford Drug Design Ltd
  • Peptilogics Inc
  • Pylum Biosciences Inc
  • Qpex Biopharma Inc
  • Redx Pharma Plc
  • RMH Sciences LLC
  • Sealife PHARMA GMBH
  • Shanghai Space Peptides Pharmaceutical Co Ltd
  • Shionogi & Co Ltd
  • Spero Therapeutics Inc
  • Summit Therapeutics Plc
  • Tetraphase Pharmaceuticals Inc
  • VenatoRx Pharmaceuticals Inc
  • Venus Medicine Research Center
  • Vitas Pharma Research Pvt Ltd
  • Xellia Pharmaceuticals ApS
Note: Product cover images may vary from those shown
Adroll
adroll